These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7791516)

  • 1. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
    Kroemer HK; Eichelbaum M
    Life Sci; 1995; 56(26):2285-98. PubMed ID: 7791516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
    Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
    Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.
    Otton SV; Schadel M; Cheung SW; Kaplan HL; Busto UE; Sellers EM
    Clin Pharmacol Ther; 1993 Nov; 54(5):463-72. PubMed ID: 7693389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
    Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
    J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquin oxidation genotype and susceptibility to lung cancer.
    Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
    Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
    Yu AM; Idle JR; Gonzalez FJ
    Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
    Thuerauf N; Lunkenheimer J
    Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
    Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
    Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethnic differences of the primary gene defect at the cytochrome P-450 2D6.
    Katoh T; Higashi K
    J UOEH; 1992 Sep; 14(3):205-9. PubMed ID: 1410938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.